

**Freedom of Information Request****Ref: UHB 17-655**

Date 23 November 2017

[REDACTED]

[REDACTED]

[REDACTED]

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

**1) How many of the following patients (excluding clinical trial patients) are currently being managed by your Health Trust:**

Patient Type	Total number of patients (treated and not treated)	Number currently treated with any active anti-cancer drug treatment (excl. surgery/ radiotherapy only)	Number not treated
All Urothelial cancer (UCC, transitional carcinoma, TCC) patients			
Metastatic* or locally advanced* Urothelial cancer (UCC, transitional carcinoma, TCC) patients			

We are unable to differentiate this data between treated and not-treated as the start of the Urological cancer pathway is at North Bristol NHS Trust; patients are only referred to our Trust if they are referred to Bristol Haematology and Oncology Centre for chemo and radiotherapy. We are therefore to provide the requested information at present.

**2) Of the metastatic\* or locally advanced\* Urothelial cancer (UCC, transitional carcinoma, TCC) patients, please state the number of patients currently being treated with the following therapies:**

See table below. Please note as the request asked for patient who are currently being treated we have included only those that have received treatment in the previous month

Therapy	Number of metastatic* or locally advanced* Urothelial cancer (UCC, transitional carcinoma, TCC) patients currently treated
Cisplatinium single agent	0
Cisplatinium in combination with another agent	5
Carboplatinium single agent	0
Carboplatinium in combination with another agent	7
Any other chemo regimen without cisplatinium or carboplatinium	**
Pembrolizumab (Keytruda)	0
Atezolizumab (Tecentriq)	0

Where the figures are fewer than 5, this has been denoted by \*\*. Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. In our view disclosure of these low figures would breach one of the Data Protection Principles set out in Schedule 1 of the Data Protection Act, namely Principle 1. Therefore under Section 40(2) of the Freedom of Information Act 2000, we will not be disclosing this information at this time. Section 40 is the exemption for personal information

**3) If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust patients are referred:**

Not applicable

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Trust Secretary  
University Hospitals Bristol NHS Foundation Trust  
Trust Headquarters  
Marlborough Street  
Bristol  
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely,

